Rigel exec uses 874 shares for tax obligations

RIGEL PHARMACEUTICALS INC (RIGL) executive David A. Santos, EVP and Chief Commercial Officer, had 874 shares of common stock delivered or withheld on September 1, 2026 to satisfy exercise price or tax liability at a reference value of $47.50 per share.

Rhea-AI Filing Summary

RIGEL PHARMACEUTICALS INC (RIGL) executive David A. Santos, EVP and Chief Commercial Officer, had 874 shares of common stock delivered or withheld on September 1, 2026 to satisfy exercise price or tax liability at a reference value of $47.50 per share. Following this transaction, he directly holds 61,622 shares, which include 500 shares acquired under the company’s stock purchase plan. No Rule 10b5-1 trading plan is indicated for this filing.

Insider Trade Summary

Exercise Price or Tax Liability: 874 shares

Exercise Price or Tax Liability 1 txn

Insider Santos David A

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock F1	874	$47.50	$42K

Holdings After Transaction: Common Stock — 61,622 shares (Direct)

Footnotes (1)

1. F1. Includes 500 shares acquired under the Issuer's stock purchase plan.

Key Figures

Shares delivered/withheld: 874 shares Per-share value: $47.50 per share Shares held after transaction: 61,622 shares +2 more

5 metrics

Shares delivered/withheld 874 shares Common stock used for payment of exercise price or tax liability on September 1, 2026

Per-share value $47.50 per share Reference price for 874 shares delivered or withheld under code F transaction

Shares held after transaction 61,622 shares Direct holdings of David A. Santos following the September 1, 2026 transaction

Shares from stock purchase plan 500 shares Portion of post-transaction holdings acquired under the issuer’s stock purchase plan

Exercise-price-or-tax-liability shares 874 shares Shares classified in transaction summary as used for exercise price or tax liability

Key Terms

Payment of exercise price or tax liability, stock purchase plan, Rule 10b5-1

3 terms

Payment of exercise price or tax liability financial

"Payment of exercise price or tax liability by delivering or withholding securities"

stock purchase plan financial

"Includes 500 shares acquired under the Issuer's stock purchase plan"

A stock purchase plan is a company-run program that lets employees or qualifying investors buy the company’s shares regularly, often through paycheck deductions and sometimes at a discounted price or with matching contributions. It matters because it encourages ownership—like a workplace discount for buying company products—aligning interests between holders and managers, while affecting share supply and potential value for outside investors.

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is indicated for this filing"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGL executive David A. Santos report on this Form 4?

David A. Santos reported that 874 RIGEL (RIGL) shares were delivered or withheld on September 1, 2026 to cover exercise price or tax liability, at a reference value of $47.50 per share, under code F (non-derivative common stock).

How many RIGL shares does David A. Santos hold after this transaction?

After the reported transaction, David A. Santos directly holds 61,622 shares of RIGEL common stock. A related footnote states that this total includes 500 shares acquired under the issuer’s stock purchase plan.

What does the code F transaction mean for the RIGL Form 4 filing?

The code F transaction means 874 shares of RIGEL common stock were delivered or withheld to pay exercise price or tax liability, rather than being a market purchase or sale. It is classified as a disposition of non-derivative common stock.

Was a Rule 10b5-1 trading plan used for this RIGL insider transaction?

No. The filing’s Rule 10b5-1 checkbox is not marked, and there is no footnote indicating a trading plan. The Form 4 therefore does not report that this transaction was made under a Rule 10b5-1 plan.

What price per share is associated with the RIGL insider’s withheld shares?

The transaction reports a value of $47.50 per share for the 874 shares delivered or withheld to cover exercise price or tax liability. This figure is labeled as a per-share amount for the non-derivative common stock involved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 07:03 PM Accepted by SEC EDGAR 09/03/2026 - 07:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos David A

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		F		874	D	$47.5	61,622(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 500 shares acquired under the Issuer's stock purchase plan.

	/s/ Raymond Furey (Attorney-in-Fact)	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)